Summary
In the recent years, we have seen a drastic increase in the antibiotic resistance among bacterial pathogens. This is considered as one of the biggest threats to global health in the current era. The reason for that is inappropriate use of antibiotics - patients are often treated with not optimal antibiotic that need to be changed after few days. Number of resistant microorganisms constantly elevates due to inappropriate use of antibiotics - patients are often treated with inappropriate drugs that need to be changed after few days if bacteria turns to be resistant. The reason for that is that current manual antibiotic resistance tests are time-consuming and laborious, while automatic antimicrobial tests offer analysis of a short lists of antibiotics.
BacterOMIC is a response to the growing global threat of antibiotic resistance. We provide the first fully comprehensive rapid Antimicrobial Susceptibility Testing (AST) system to determine already in 4h which from all common antibiotics will be most successful in treating certain bacterial infection. Unlike current methods, our system also allows to investigate antimicrobial effect of not only single antibiotics but also combinations of multiple antibiotics – the future of infection disease treatment.
Constantly growing antimicrobial susceptibility testing market was valued at EUR 2.4 billion in 2018 and is expected to reach EUR 3.1 billion by 2022 at the CAGR of 5.1%. With our clear business model we target pharmaceutical and biotechnology companies, contract research organizations, hospitals/private healthcare centers, and diagnostic laboratories. We have a network of partnerships across the EU (PL, FR, ES, CH, DE, and PT) and we are ready for rapid scale-up, with more than 30 million cumulative profit by 2025. We need SME Instrument phase 2 to optimize the design, prepare for mass production, validate the system in clinical trials, and certify it for successful commercialization.
BacterOMIC is a response to the growing global threat of antibiotic resistance. We provide the first fully comprehensive rapid Antimicrobial Susceptibility Testing (AST) system to determine already in 4h which from all common antibiotics will be most successful in treating certain bacterial infection. Unlike current methods, our system also allows to investigate antimicrobial effect of not only single antibiotics but also combinations of multiple antibiotics – the future of infection disease treatment.
Constantly growing antimicrobial susceptibility testing market was valued at EUR 2.4 billion in 2018 and is expected to reach EUR 3.1 billion by 2022 at the CAGR of 5.1%. With our clear business model we target pharmaceutical and biotechnology companies, contract research organizations, hospitals/private healthcare centers, and diagnostic laboratories. We have a network of partnerships across the EU (PL, FR, ES, CH, DE, and PT) and we are ready for rapid scale-up, with more than 30 million cumulative profit by 2025. We need SME Instrument phase 2 to optimize the design, prepare for mass production, validate the system in clinical trials, and certify it for successful commercialization.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/881101 |
| Start date: | 01-08-2019 |
| End date: | 31-12-2021 |
| Total budget - Public funding: | 2 752 387,00 Euro - 1 926 671,00 Euro |
Cordis data
Original description
In the recent years, we have seen a drastic increase in the antibiotic resistance among bacterial pathogens. This is considered as one of the biggest threats to global health in the current era. The reason for that is inappropriate use of antibiotics - patients are often treated with not optimal antibiotic that need to be changed after few days. Number of resistant microorganisms constantly elevates due to inappropriate use of antibiotics - patients are often treated with inappropriate drugs that need to be changed after few days if bacteria turns to be resistant. The reason for that is that current manual antibiotic resistance tests are time-consuming and laborious, while automatic antimicrobial tests offer analysis of a short lists of antibiotics.BacterOMIC is a response to the growing global threat of antibiotic resistance. We provide the first fully comprehensive rapid Antimicrobial Susceptibility Testing (AST) system to determine already in 4h which from all common antibiotics will be most successful in treating certain bacterial infection. Unlike current methods, our system also allows to investigate antimicrobial effect of not only single antibiotics but also combinations of multiple antibiotics – the future of infection disease treatment.
Constantly growing antimicrobial susceptibility testing market was valued at EUR 2.4 billion in 2018 and is expected to reach EUR 3.1 billion by 2022 at the CAGR of 5.1%. With our clear business model we target pharmaceutical and biotechnology companies, contract research organizations, hospitals/private healthcare centers, and diagnostic laboratories. We have a network of partnerships across the EU (PL, FR, ES, CH, DE, and PT) and we are ready for rapid scale-up, with more than 30 million cumulative profit by 2025. We need SME Instrument phase 2 to optimize the design, prepare for mass production, validate the system in clinical trials, and certify it for successful commercialization.
Status
CLOSEDCall topic
EIC-SMEInst-2018-2020Update Date
27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Search
